Bacterial expression and ligand binding of purified domains of Stabilin-2

Lauren Vatter Author

08/01/2021 Added

9 Plays

Description

This summer I worked to characterize the ligand binding on the Stabilin-2 receptor found in the liver.

Searchable Transcript

Search:

[00:00:00.270]And it was Lauren and I will be taking you through, um,
[00:00:03.810]my you care project this summer, which is entitled that bacterial expression,
[00:00:07.380]like in binding a purified domains to build.
[00:00:09.530]And to I focused on this a lot this summer,
[00:00:13.050]I did a little bit of research on this towards the end of last semester,
[00:00:17.430]but this is the main focus of my research this semester or
[00:00:22.410]the summer I should say.
[00:00:24.360]So basically I'm going to start with a little background information
[00:00:27.360]introduction about why we do this research. What's the significance of it?
[00:00:31.590]So heparin is a very important anticoagulant used in hospitals and outpatient
[00:00:36.060]care. It's one of the top 10 drugs that's used in hospitals.
[00:00:39.870]So it's very prevalent in medicine today. We,
[00:00:43.200]it's very important that we know how it interacts with our body.
[00:00:47.160]So there are two different forms of heparin,
[00:00:48.990]the unfractionated and the low molecular weight heparin unfractionated heparin
[00:00:53.100]is used more in hospitals because medical professionals have to really control
[00:00:58.080]the dosage of that.
[00:00:59.250]And then low molecular weight heparin is basically what it sounds like.
[00:01:03.120]It's a smaller, um, molecular weight. It's basically fractionated heparin. Um,
[00:01:07.620]so it's the, uh,
[00:01:09.450]heparin molecule is just split apart and that is more used in
[00:01:14.040]outpatient care because it does not need, um, constant supervision
[00:01:19.500]of dosages.
[00:01:21.000]And so antisense Akio nucleotides also known as Osos are
[00:01:25.830]also a drug that's used in drug therapies to correcting splicing
[00:01:30.780]and for knockout genes and, and receptors.
[00:01:34.230]Catabolize both ASSP and heparin.
[00:01:37.200]There are two stability receptors to build on one and stubble in twos to build
[00:01:40.500]in to, um,
[00:01:41.640]does most of this catabolism patient interacts with these drugs such as ASO and
[00:01:46.560]heparin. So that's what we used in our research.
[00:01:50.100]That is what we study stability to.
[00:01:52.200]And stability two is a 315 kilodalton receptor.
[00:01:56.940]Um, but it can also be cleaved into a 198.
[00:02:01.200]Kilodalton variant known as one 90 hair and hyaluronic acid is the
[00:02:06.090]first known ligand that binds with [inaudible] and hyaluronic acid is important
[00:02:10.590]when we assess the ligand binding and our research that I will talk about a
[00:02:14.550]little bit later.
[00:02:15.990]And this graphic here is just kind of showing the stubble and receptors.
[00:02:20.550]So up here, we have stubborn one,
[00:02:22.800]the receptor that we don't really study that doesn't, um,
[00:02:26.580]it interacts with heparin and ISO's, but it does it to a lesser extent.
[00:02:31.230]So here we have stubble into,
[00:02:33.810]this is the 315 kilodalton variant, obviously it's the longer one.
[00:02:38.970]And then under we have one 90 hair.
[00:02:41.820]So the interesting thing about stability, um,
[00:02:44.880]the 315 killed on very enough stability in one 90 hair is
[00:02:49.500]that, um,
[00:02:50.400]it binds at 19 ligans and all of the ligans that bind to a
[00:02:54.990]stubble and to also bind to one 90 hair.
[00:02:57.990]So it's been concluded that all of the binding
[00:03:02.830]happens in the latter two thirds of the receptor.
[00:03:06.050]So basically this part does not bind to any ligands.
[00:03:09.040]It's just this part right here.
[00:03:14.770]So the objective and purpose of this research, so stability to, as I said,
[00:03:19.570]binds 19 different logins,
[00:03:20.980]but only two of those ligands have been characterized.
[00:03:23.320]So what about the other 17? That is what we're researching.
[00:03:26.740]So we're researching what region of spilling two interacts with these
[00:03:30.130]electronegative polymers and the characterization of those logins,
[00:03:35.470]and do that through a six step methodology, um,
[00:03:38.890]to evaluate this ligand binding. So we go through PCR transformation,
[00:03:43.510]the verification that we transform the correct plasma and the protein
[00:03:47.110]expression, protein purification and ligand binding, which can be, um,
[00:03:51.700]outlined here in this little graphic.
[00:03:54.370]So I'll explain each of these methodologies in more detail.
[00:03:58.720]So first we have PCR. So we start with PCR.
[00:04:03.850]So we anneal C3 and C4,
[00:04:07.060]which is basically just shorthand for the third and fourth EGF
[00:04:11.500]clusters on the one 90 hair receptor.
[00:04:15.940]So we nail those and we like get them into a pet 43.1
[00:04:20.470]factor. And we also work with an empty pet vector. And I also, this,
[00:04:25.710]this summer, I heavily worked with the link domain as well.
[00:04:31.000]So once these, uh, [inaudible] these,
[00:04:35.410]the link domain is ly gated into the pet factor.
[00:04:39.940]All of this recombinant protein has a six S his tag,
[00:04:42.550]which is important for the protein purification that we'll talk about later on.
[00:04:47.560]So the next step, well, first I'll talk about this, um, gel right here.
[00:04:51.790]So basically we have in this gel,
[00:04:55.180]I annealed to different parts of the
[00:04:59.710][inaudible] EGF Z four, excuse me, as you for EGF cluster.
[00:05:03.550]So we have 6, 6, 7, 8, 6, 7 5 4 here,
[00:05:07.360]which is basically just different places on this cluster.
[00:05:11.080]And then we have the link domain here, as well, as I said,
[00:05:13.240]I worked a lot with that this semester. And so, um,
[00:05:17.200]I ran on the gel to see where they were after I ran a PCR on them and then cut
[00:05:21.910]them out. And then we moved onto the transformation. So,
[00:05:26.650]and transformation process. It's basically exactly as it sounds,
[00:05:30.310]we transformed the plasmids into Nikolai and we run them on gel to verify the
[00:05:34.540]presence of inserts here. We have, um,
[00:05:39.220]uh, big gel that I ran,
[00:05:41.060]I believe it has 18 different, um,
[00:05:46.120]colonies that I'm looking at 18 different plasmids that I'm looking at. Um,
[00:05:50.260]and sadly, this gel was, uh, pretty unsuccessful.
[00:05:55.210]The inserts did not really work. They weren't, um, my gated properly,
[00:06:00.830]they just didn't work out, but the last two here are, um,
[00:06:05.030]empty pet doctors. And so, um,
[00:06:08.180]those actually did run as they should.
[00:06:11.270]So I was able to just cut out the empty pet vector
[00:06:15.920]and a mini prep that, and work with that for a little bit.
[00:06:20.930]Um,
[00:06:21.320]so then the next step in the methodology is to verify that we
[00:06:26.240]have the correct classmen. So once, um, this, the previous side,
[00:06:30.770]this gel was just one of the many gels that I ran, um, to, um,
[00:06:35.510]verify the plasma it's free there.
[00:06:37.370]And so once I actually do get inserts that work,
[00:06:40.280]we have to verify that it's the correct plasma.
[00:06:42.980]So we do that through the restriction enzyme digest.
[00:06:46.520]So I mainly worked with bam, H I and eco I this summer,
[00:06:51.530]just cause we know exactly where that cuts in the, um,
[00:06:57.200]receptor. So I was able to cut them. And this is just an example of a job that,
[00:07:02.180]um, I ran that has,
[00:07:04.130]I believe it's still with 6, 6, 7, 8, 6 7 5 4, and then link it again.
[00:07:09.140]So we just wanted to ensure that they were actually the right size of plasma and
[00:07:13.880]everything was correct there.
[00:07:15.080]And once that is verified through the restriction enzymes digest that all the
[00:07:19.160]fragments are correct. We send the DNI off to be sequenced,
[00:07:23.120]to ensure there's no view mutations like a frameshift or drop out or anything
[00:07:27.230]like that. So once all of that is verified that, um,
[00:07:31.250]everything with the plasma and the DNA is correct,
[00:07:34.550]we move on to protein expression. So protein expression is,
[00:07:39.230]um,
[00:07:40.100]where we transform the plasmids into BL 21 or
[00:07:44.930]gummy Ecolab. So
[00:07:49.270]beautiful 21 cells are a special type of Nikolai because they
[00:07:53.980]are specialized for protein, folding and expression.
[00:07:57.550]So it just gives us a better shot of the protein being expressed correctly and
[00:08:02.440]fully when we transform them into these origami cells.
[00:08:07.090]So first this is kind of a three-day process over here.
[00:08:10.780]We have a gel of when we transform them into these origami cells and the gel
[00:08:15.700]itself didn't really turn out great. It's a little bit blurry. Um,
[00:08:20.080]I ran it multiple times and it kind of was still this blurry, um, thing,
[00:08:24.160]but we were able to verify that the, uh,
[00:08:28.390]plasmid was there. So we were able to first grow them up in a small culture,
[00:08:33.430]about three milliliters. And then once that it's grown up,
[00:08:37.870]we grow it up into a one or two liter culture overnight.
[00:08:42.700]And then finally we have an induced culture when we induce it with IP TG.
[00:08:48.100]So when we're working with [inaudible] the three pet,
[00:08:52.540]we induce them all with IP TG,
[00:08:55.260]and then we have to purify those proteins from the big
[00:08:59.520]cultures. So that there's two ways to do that.
[00:09:04.020]And I primarily only did French press. I only did French press.
[00:09:08.850]So, um, that's the only one. All we talking about, we can also use on occasion,
[00:09:12.930]but I did not do that this summer.
[00:09:15.060]So basically the French press is a machine where that applies a lot of pressure
[00:09:19.050]and breaks the cell open. So all of the genetic material comes out the DNA,
[00:09:23.760]the protein that we want. Um,
[00:09:26.790]so the proteins then run through a nickel resin,
[00:09:30.960]and this is where the success his tag comes in because that basically gets stuck
[00:09:35.160]in the nickel resident through interaction.
[00:09:37.320]And the protein is stuck in the resin and it's washed with a
[00:09:41.940]solvent to purify it. And it can either be, um,
[00:09:45.360]it can either remain in the column or be alluded.
[00:09:48.180]And this summer I alluded the proteins,
[00:09:51.930]I alluded them all. So, um, the next step is look in binding.
[00:09:56.370]That's what we're testing for.
[00:09:57.810]We want to see how well does the protein that we
[00:10:02.040]purified bind ligans.
[00:10:04.920]So there are two options to determine ligand binding,
[00:10:07.620]but I only did one this semester. I only did colorimetric assay's specifically,
[00:10:11.850]I did one BCA assay. So, uh,
[00:10:15.360]basically the protein is alluded from the column just using on the elution
[00:10:18.690]buffer. And then, and anybody is used to mobilize the protein.
[00:10:22.770]I believe we used a rabbit antibody this summer,
[00:10:26.040]and then the presence of the login is used, uh,
[00:10:28.830]is measured using a colorimetric assay. Like I said,
[00:10:31.500]I used a BCA assay and, um,
[00:10:34.380]basically the amount of color that, um,
[00:10:39.300]is shown in each sample can tell us how much ligand
[00:10:44.190]is bound to that.
[00:10:46.350]So I only did one BCA assay just because it takes quite a
[00:10:51.300]little bit of time to get through all these steps to make sure everything's
[00:10:53.940]right, and then you have to go back and we do it if it's not.
[00:10:56.580]So I did one BCA assay this summer to assess the ligand binding.
[00:11:01.170]And these are the results from that, which makes sense.
[00:11:04.620]There should be a little bit more ligand binding than this,
[00:11:06.900]but the ratios make sense. And that is the four is the most, um,
[00:11:11.580]has the most with, uh, 10 micrograms per milliliter.
[00:11:15.480]C3 is next where it's kind of stuck in the middle with, um,
[00:11:19.710]seven micrograms per milliliter and then pet, which is just the empty vector,
[00:11:24.510]like I said, has six micrograms per milliliter. So the least amount.
[00:11:28.740]And so in conclusion, and the further directions of this experiment,
[00:11:33.780]a benchmark for my research was being able to
[00:11:38.520]complete the methodologies independently and proficiently.
[00:11:42.480]And I am happy to say that I was able to complete almost all the methodologies
[00:11:46.740]independently. I was able to,
[00:11:48.660]I did all of the methodologies I ran through with this experiment many times.
[00:11:52.680]Um, I did one VCA asset, like I said,
[00:11:56.860]but I had help from Dr. Harris with that.
[00:11:59.320]So I can't say I did that independently,
[00:12:01.420]but I believe that it's a great benchmark, um,
[00:12:03.850]a great show of my progress and growth through you care that I was able to do
[00:12:08.710]these, these processes independently, especially French press,
[00:12:12.700]because I know it's not a common thing for undergraduates to be able to do that.
[00:12:16.960]And I was able to do that multiple times independently,
[00:12:20.200]which I think is very cool. And so, uh, further directions.
[00:12:24.790]So purified proteins that went through the nickel resin and
[00:12:29.350]everything were incubated with radioactive hyaluronic acid to quantify and
[00:12:32.740]Lincoln ligand binding, which like I said, um, hyaluronic acid was the first,
[00:12:38.020]um, ligan to be discovered that bond bound to the stimulant two receptor.
[00:12:42.540]And obviously I am not qualified to be really handling radioactive
[00:12:46.980]material.
[00:12:47.560]Seeing I'm as I am junior in college.
[00:12:50.040]But I just, my Dr. Harris stepped in.
[00:12:52.980]So that's just a further direction just to assess how, um,
[00:12:57.000]that liquid binding we, um, are able to just, uh,
[00:13:00.390]look how the radioactive tags are bound to the different receptors.
[00:13:05.760]And then next week we are just going to grow up some more clowns and kind of
[00:13:09.990]start the process all over again, starting from, um,
[00:13:14.820]I believe that we're going to start from the transformation.
[00:13:17.190]So with the Biel 21 cells,
[00:13:20.100]but that is basically all of my research this semester.
[00:13:23.790]So thank you. That's basically all I've done.
[00:13:26.520]Thank you for listening to what I have been doing all summer.

The screen size you are trying to search captions on is too small!

You can always jump over to MediaHub and check it out there.

Comments

0 Comments

Bacterial expression and ligand binding of purified domains of Stabilin-2

Description

Searchable Transcript

Comments icon comment

Related Channels

Comments